DK3400217T3 - L-valinat af hydroxypropylthiazolidincarboxamid-derivat, dets salt og krystalform deraf - Google Patents

L-valinat af hydroxypropylthiazolidincarboxamid-derivat, dets salt og krystalform deraf Download PDF

Info

Publication number: DK3400217T3
Authority: DK; Denmark
Prior art keywords: valinate; salt; crystal form; carboxamide derivatives; hydroxypropylthiazolidine
Prior art date: 2016-01-04

Application number

DK17700392.8T

Other languages

English (en)

Inventor

Page Patrick Naxos

Matthias Schwarz

Catherine Jorand-Lebrun

Vincent Pomel

Anna Quattropani

Original Assignee

Merck Serono Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2016-01-04

Filing date

2017-01-04

Publication date

2022-06-07

2016-01-04 Priority claimed from US14/987,586 external-priority patent/US9447055B1/en

2017-01-04 Application filed by Merck Serono Sa filed Critical Merck Serono Sa

2022-06-07 Application granted granted Critical

2022-06-07 Publication of DK3400217T3 publication Critical patent/DK3400217T3/da

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/095—Oxytocins; Vasopressins; Related peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/04—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D277/06—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Epidemiology (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Reproductive Health (AREA)
Endocrinology (AREA)
Gastroenterology & Hepatology (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Pregnancy & Childbirth (AREA)
Gynecology & Obstetrics (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Thiazole And Isothizaole Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Cephalosporin Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pyrrole Compounds (AREA)
Rheumatology (AREA)
Pain & Pain Management (AREA)
Peptides Or Proteins (AREA)
Investigating Or Analysing Biological Materials (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Emergency Medicine (AREA)

DK17700392.8T 2016-01-04 2017-01-04 L-valinat af hydroxypropylthiazolidincarboxamid-derivat, dets salt og krystalform deraf DK3400217T3 (da)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
US201662274674P	2016-01-04	2016-01-04
US14/987,586 US9447055B1 (en)	2016-01-04	2016-01-04	α-amino esters of hydroxypropylthiazolidine carboxamide derivative and salt form, crystal polymorph thereof
US201662395664P	2016-09-16	2016-09-16
US201662407918P	2016-10-13	2016-10-13
PCT/EP2017/050101 WO2017118641A1 (en)	2016-01-04	2017-01-04	L-valinate of hydroxypropylthiazolidine carboxamide derivative and salt form, crystal polymorph thereof

Publications (1)

Publication Number	Publication Date
DK3400217T3 true DK3400217T3 (da)	2022-06-07

Family

ID=57799697

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
DK17700392.8T DK3400217T3 (da)	2016-01-04	2017-01-04	L-valinat af hydroxypropylthiazolidincarboxamid-derivat, dets salt og krystalform deraf
DK17700391.0T DK3397622T3 (en)	2016-01-04	2017-01-04	Co-administration af alpha-aminoester af hydroxypropylthiazolidincarboxamid-derivat og et tokolytisk middel

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
DK17700391.0T DK3397622T3 (en)	2016-01-04	2017-01-04	Co-administration af alpha-aminoester af hydroxypropylthiazolidincarboxamid-derivat og et tokolytisk middel

Country Status (25)

Country	Link
EP (4)	EP3397622B1 (da)
JP (5)	JP7169573B2 (da)
KR (3)	KR20180100120A (da)
CN (1)	CN108779087A (da)
AU (4)	AU2017205670B2 (da)
CA (2)	CA3009576A1 (da)
CY (2)	CY1125231T1 (da)
DK (2)	DK3400217T3 (da)
EA (1)	EA036990B1 (da)
ES (2)	ES2916835T3 (da)
HR (2)	HRP20220673T1 (da)
HU (2)	HUE058872T2 (da)
IL (5)	IL318222A (da)
LT (2)	LT3400217T (da)
MA (2)	MA43580A (da)
MX (3)	MX379544B (da)
PL (2)	PL3397622T3 (da)
PT (2)	PT3397622T (da)
RS (2)	RS63286B1 (da)
SG (4)	SG10202009723PA (da)
SI (2)	SI3400217T1 (da)
SM (2)	SMT202200248T1 (da)
UA (2)	UA125118C2 (da)
WO (2)	WO2017118639A1 (da)
ZA (1)	ZA201903769B (da)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DK3400217T3 (da) *	2016-01-04	2022-06-07	Merck Serono Sa	L-valinat af hydroxypropylthiazolidincarboxamid-derivat, dets salt og krystalform deraf
RU2711615C1 (ru) *	2019-09-12	2020-01-17	Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт акушерства, гинекологии и репродуктологии имени Д.О. Отта"	Способ лечения эндометриоза на основании экспериментальной модели у крыс
WO2021061847A1 (en) *	2019-09-23	2021-04-01	The Board Of Trustees Of The Leland Stanford Junior University	Methods of treatments to prolong gestation and complications of menstruation or gestation
US12426782B2 (en)	2020-11-06	2025-09-30	The Board Of Trustees Of The Leland Stanford Junior University	Systems and temporal alignment methods for evaluation of gestational age and time to delivery
CA3204921A1 (en) *	2020-12-11	2022-06-16	Elise A. Olsen	Compositions and methods for inhibiting hair growth

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3835175A (en)	1971-03-15	1974-09-10	Research Corp	9-fluorenylmethanol haloformates, carbonates and thiocarbonates
US3839396A (en)	1971-07-15	1974-10-01	Shionogi & Co	9-lower alkyl-9-fluorenyl carbonates
US4108846A (en)	1977-02-01	1978-08-22	Hoffmann-La Roche Inc.	Solid phase synthesis with base N alpha-protecting group cleavage
SE430885B (sv)	1980-03-24	1983-12-19	Ferring Ab	Oxytocin-derivat
US4508657A (en)	1982-01-19	1985-04-02	Research Corporation	Peptide synthesis and amino acid blocking agents
US4581167A (en)	1982-01-19	1986-04-08	Research Corporation	Peptide synthesis and amino acid blocking agents
ATE20072T1 (de)	1982-12-21	1986-06-15	Ferring Ab	Vasotocinderivate.
US4460501A (en)	1983-08-30	1984-07-17	Research Corporation	Process for the synthesis of peptides utilizing thioxanthylmethyloxycarbonyl dioxides
US5370135A (en) *	1993-10-13	1994-12-06	Biex, Inc.	Use of estriol measurement to monitor tocolytic therapy
DE4434488A1 (de) *	1994-09-14	1996-03-21	Schering Ag	Steroidester und -amide, Verfahren zu ihrer Herstellung und ihre pharmazeutische Verwendung
SE9604341D0 (sv)	1996-11-26	1996-11-26	Ferring Bv	Hepta-peptide oxytocin analogue
IN188411B (da) *	1997-03-27	2002-09-21	Yuhan Corp
WO2001092267A2 (en) *	2000-05-30	2001-12-06	Ortho-Mcneil Pharmaceutical, Inc.	Dihydropyridine compounds for the inhibition of calcium-influx
GB0130677D0 (en)	2001-12-21	2002-02-06	Glaxo Group Ltd	Medicaments and novel compounds
ES2277640T3 (es)	2002-02-27	2007-07-16	Ferring Bv	Productos intermedios y metodos para preparar analogos de heptapeptido de oxitocina.
JP4602672B2 (ja) *	2002-03-28	2010-12-22	メルクセローノソシエテアノニム	プロスタグランジンｆ受容体のモジュレーターとしてのチアゾリジンカルボキサミド誘導体
GB0208785D0 (en) *	2002-04-17	2002-05-29	Medical Res Council	Treatment methtods
US7521530B2 (en) *	2002-06-11	2009-04-21	Universite De Montreal	Peptides and peptidomimetics useful for inhibiting the activity of prostaglandin F2α receptor
UA78058C2 (en)	2002-07-05	2007-02-15	Applied Research Systems	Pyrrolidine derivative as oxitocin antagonists
RU2005121904A (ru) *	2002-12-12	2006-01-20	Айденикс (Кайман) Лимитед (Ky)	Способ получения 2`-разветвленных нуклеозидов
GB0314738D0 (en)	2003-06-24	2003-07-30	Glaxo Group Ltd	Novel compounds
GB0414093D0 (en)	2004-06-23	2004-07-28	Glaxo Group Ltd	Novel compounds
US8716286B2 (en)	2009-10-30	2014-05-06	Glaxo Group Limited	Crystalline forms of (3R, 6R)-3-(2,3-dihydro-1H-inden-2-yl)-1-[(1R)-1-(2,6-dimethyl-3-pyridinyl)-2-(4-morpholinyl)-2-oxoethyl]-6-[(1S)-1-methylpropyl]-2,5-piperazinedione
EP2845850A1 (en)	2013-09-10	2015-03-11	ObsEva S.A.	Pyrrolidine derivatives as oxytocin/vasopressin V1a receptors antagonists
EP2886107A1 (en)	2013-12-17	2015-06-24	ObsEva S.A.	Oral formulations of pyrrolydine derivatives
WO2015192878A1 (en) *	2014-06-16	2015-12-23	Glaxosmithkline Intellectual Property Development Limited	Retosiban for the treatment of pre-term labour
CA2953722C (en)	2014-07-02	2022-09-13	ObsEva SA	Crystalline (3z,5s)-5-(hydroxymethyl)-1-[(2'-methyl-1,1'-biphenyl-4-yl)carbonyl]pyrrolidin-3-one o-methyloxime, and methods of using the same
ES2716862T3 (es)	2014-12-22	2019-06-17	Ferring Bv	Terapia con antagonistas del receptor de oxitocina en la fase lútea para la implantación y embarazo en mujeres que se someten a tecnologías de reproducción asistida
US9447055B1 (en) *	2016-01-04	2016-09-20	Merck Serono S.A.	α-amino esters of hydroxypropylthiazolidine carboxamide derivative and salt form, crystal polymorph thereof
DK3400217T3 (da) *	2016-01-04	2022-06-07	Merck Serono Sa	L-valinat af hydroxypropylthiazolidincarboxamid-derivat, dets salt og krystalform deraf

2017
- 2017-01-04 DK DK17700392.8T patent/DK3400217T3/da active
- 2017-01-04 RS RS20220548A patent/RS63286B1/sr unknown
- 2017-01-04 DK DK17700391.0T patent/DK3397622T3/da active
- 2017-01-04 PL PL17700391T patent/PL3397622T3/pl unknown
- 2017-01-04 EP EP17700391.0A patent/EP3397622B1/en active Active
- 2017-01-04 JP JP2018529284A patent/JP7169573B2/ja active Active
- 2017-01-04 SG SG10202009723PA patent/SG10202009723PA/en unknown
- 2017-01-04 HR HRP20220673TT patent/HRP20220673T1/hr unknown
- 2017-01-04 LT LTEPPCT/EP2017/050101T patent/LT3400217T/lt unknown
- 2017-01-04 MX MX2018008304A patent/MX379544B/es unknown
- 2017-01-04 IL IL318222A patent/IL318222A/en unknown
- 2017-01-04 UA UAA201806830A patent/UA125118C2/uk unknown
- 2017-01-04 UA UAA201806074A patent/UA125377C2/uk unknown
- 2017-01-04 ES ES17700392T patent/ES2916835T3/es active Active
- 2017-01-04 MX MX2018008157A patent/MX389261B/es unknown
- 2017-01-04 PT PT177003910T patent/PT3397622T/pt unknown
- 2017-01-04 EP EP22153566.9A patent/EP4144351A1/en active Pending
- 2017-01-04 HU HUE17700391A patent/HUE058872T2/hu unknown
- 2017-01-04 SG SG11201804594YA patent/SG11201804594YA/en unknown
- 2017-01-04 RS RS20220547A patent/RS63285B1/sr unknown
- 2017-01-04 EA EA201891095A patent/EA036990B1/ru unknown
- 2017-01-04 HU HUE17700392A patent/HUE058871T2/hu unknown
- 2017-01-04 WO PCT/EP2017/050099 patent/WO2017118639A1/en not_active Application Discontinuation
- 2017-01-04 LT LTEPPCT/EP2017/050099T patent/LT3397622T/lt unknown
- 2017-01-04 EP EP22152238.6A patent/EP4140988A1/en active Pending
- 2017-01-04 MA MA043580A patent/MA43580A/fr unknown
- 2017-01-04 SI SI201731161T patent/SI3400217T1/sl unknown
- 2017-01-04 SI SI201731162T patent/SI3397622T1/sl unknown
- 2017-01-04 JP JP2018529634A patent/JP6933322B2/ja active Active
- 2017-01-04 KR KR1020187018312A patent/KR20180100120A/ko not_active Ceased
- 2017-01-04 WO PCT/EP2017/050101 patent/WO2017118641A1/en active Application Filing
- 2017-01-04 SM SM20220248T patent/SMT202200248T1/it unknown
- 2017-01-04 AU AU2017205670A patent/AU2017205670B2/en active Active
- 2017-01-04 HR HRP20220674TT patent/HRP20220674T1/hr unknown
- 2017-01-04 EP EP17700392.8A patent/EP3400217B1/en active Active
- 2017-01-04 KR KR1020257022032A patent/KR20250107965A/ko active Pending
- 2017-01-04 KR KR1020187018929A patent/KR102795275B1/ko active Active
- 2017-01-04 SM SM20220249T patent/SMT202200249T1/it unknown
- 2017-01-04 PL PL17700392T patent/PL3400217T3/pl unknown
- 2017-01-04 SG SG11201804789QA patent/SG11201804789QA/en unknown
- 2017-01-04 IL IL284912A patent/IL284912B/en unknown
- 2017-01-04 AU AU2017205254A patent/AU2017205254B2/en active Active
- 2017-01-04 PT PT177003928T patent/PT3400217T/pt unknown
- 2017-01-04 SG SG10202009769WA patent/SG10202009769WA/en unknown
- 2017-01-04 CA CA3009576A patent/CA3009576A1/en active Pending
- 2017-01-04 MA MA043549A patent/MA43549A/fr unknown
- 2017-01-04 CA CA3009573A patent/CA3009573A1/en active Pending
- 2017-01-04 ES ES17700391T patent/ES2915948T3/es active Active
- 2017-01-04 CN CN201780015011.9A patent/CN108779087A/zh active Pending
2018
- 2018-05-31 IL IL259742A patent/IL259742B/en unknown
- 2018-06-26 IL IL260286A patent/IL260286B/en unknown
- 2018-06-29 MX MX2022000154A patent/MX2022000154A/es unknown
2019
- 2019-05-24 ZA ZA2019/03769A patent/ZA201903769B/en unknown
2021
- 2021-08-05 JP JP2021129297A patent/JP7432284B2/ja active Active
- 2021-08-16 AU AU2021218009A patent/AU2021218009B2/en active Active
- 2021-12-22 IL IL289256A patent/IL289256A/en unknown
2022
- 2022-06-01 CY CY20221100384T patent/CY1125231T1/el unknown
- 2022-06-01 CY CY20221100383T patent/CY1125223T1/el unknown
- 2022-10-18 JP JP2022166814A patent/JP7377588B2/ja active Active
2023
- 2023-09-21 AU AU2023233151A patent/AU2023233151A1/en active Pending
- 2023-10-25 JP JP2023183345A patent/JP2024012376A/ja active Pending

Also Published As

Publication number	Publication date
CA3009576A1 (en)	2017-07-13
LT3400217T (lt)	2022-06-27
AU2021218009B2 (en)	2023-06-22
KR20180100120A (ko)	2018-09-07
SG11201804789QA (en)	2018-07-30
SI3397622T1 (sl)	2022-07-29
JP2019501897A (ja)	2019-01-24
JP7432284B2 (ja)	2024-02-16
EA201891095A1 (ru)	2019-01-31
SG10202009723PA (en)	2020-11-27
MX389261B (es)	2025-03-20
IL289256A (en)	2022-02-01
PT3397622T (pt)	2022-06-15
MA43580A (fr)	2021-05-26
HUE058871T2 (hu)	2022-09-28
HRP20220674T1 (hr)	2022-07-22
CA3009573A1 (en)	2017-07-13
EP3400217B1 (en)	2022-03-09
HRP20220673T1 (hr)	2022-07-08
CY1125231T1 (el)	2025-03-28
UA125118C2 (uk)	2022-01-12
CN108779087A (zh)	2018-11-09
RS63286B1 (sr)	2022-06-30
UA125377C2 (uk)	2022-03-02
MX379544B (es)	2025-03-11
ZA201903769B (en)	2023-03-29
KR20180099708A (ko)	2018-09-05
KR102795275B1 (ko)	2025-04-11
IL284912B (en)	2022-07-01
IL284912A (en)	2021-08-31
MX2018008304A (es)	2019-01-24
IL259742B (en)	2021-08-31
WO2017118639A1 (en)	2017-07-13
WO2017118641A1 (en)	2017-07-13
DK3397622T3 (en)	2022-06-07
IL260286B (en)	2022-02-01
EA036990B1 (ru)	2021-01-25
JP2019500351A (ja)	2019-01-10
AU2017205254A1 (en)	2018-08-16
EP3400217A1 (en)	2018-11-14
HUE058872T2 (hu)	2022-09-28
EP3397622A1 (en)	2018-11-07
JP7169573B2 (ja)	2022-11-11
SMT202200248T1 (it)	2022-07-21
MX2018008157A (es)	2018-09-03
AU2017205254B2 (en)	2021-05-20
EP3397622B1 (en)	2022-03-09
JP2023002668A (ja)	2023-01-10
RS63285B1 (sr)	2022-06-30
SMT202200249T1 (it)	2022-07-21
SG10202009769WA (en)	2020-11-27
PL3400217T3 (pl)	2022-07-04
AU2017205670A1 (en)	2018-08-16
KR20250107965A (ko)	2025-07-14
EP4144351A1 (en)	2023-03-08
JP7377588B2 (ja)	2023-11-10
AU2017205670B2 (en)	2021-05-20
JP2021178858A (ja)	2021-11-18
IL318222A (en)	2025-03-01
MA43549A (fr)	2021-05-26
IL259742A (en)	2018-07-31
ES2916835T3 (es)	2022-07-06
PT3400217T (pt)	2022-06-15
SG11201804594YA (en)	2018-06-28
MX2022000154A (es)	2022-02-21
PL3397622T3 (pl)	2022-07-04
AU2023233151A1 (en)	2023-10-12
EP4140988A1 (en)	2023-03-01
CY1125223T1 (el)	2025-03-28
SI3400217T1 (sl)	2022-07-29
AU2021218003A1 (en)	2021-09-02
JP2024012376A (ja)	2024-01-30
AU2021218009A1 (en)	2021-09-09
IL260286A (en)	2018-07-31
LT3397622T (lt)	2022-06-27
JP6933322B2 (ja)	2021-09-08
ES2915948T3 (es)	2022-06-27

Publication	Publication Date	Title
DK3728254T3 (da)	2023-06-06	Benzylamin-substituerede pyridopyrimidinoner og derivater som sos1-inhibitorer
DK3474996T3 (da)	2021-05-03	Tågeapparat og anvendelsesmåde
DK3452463T3 (da)	2021-04-26	Amidsubstituerede pyridinyltriazolderivater og anvendelser deraf
DK3331894T3 (da)	2021-03-22	Nicotinamidmononukleotidderivater og anvendelser deraf
PL3578547T3 (pl)	2021-12-20	Pochodne sulfonylomocznika i związki pokrewne oraz ich zastosowanie
DK3269809T3 (da)	2022-09-12	MODIFICERET AMINOACYL-tRNA-SYNTETASE OG ANVENDELSE DERAF
EP3548497A4 (en)	2020-09-02	SEPIAPTERIN POLYMORPHS AND THEIR SALTS
DK3236991T3 (da)	2019-08-26	Fgf21-derivater og anvendelser deraf
DK3099800T3 (da)	2021-01-11	Ekspression og oprensning af crm197 og beslægtede proteiner
DK3215493T3 (da)	2019-05-06	Syntese af copanlisib og dihydrochloridsalt deraf
EP3551625A4 (en)	2020-09-16	HETEROCYCLIC MCT4 INHIBITORS
LT3512833T (lt)	2020-10-12	Heteroarilo karboksamido junginiai kaip ripk2 inhibitoriai
DK3067355T3 (da)	2021-01-04	Krystaller af diazabicyclooctanderivat og fremgangsmåde til fremstilling af krystaller af diazabicyclooctanderivat
EP3654987A4 (en)	2021-04-28	USE OF AMINOALKYLBENZOTHIAZEPINE DERIVATIVES
DK3400217T3 (da)	2022-06-07	L-valinat af hydroxypropylthiazolidincarboxamid-derivat, dets salt og krystalform deraf
DK3389669T3 (da)	2023-05-01	Triterpensaponinvarianter, syntesefremgangsmåder og anvendelse deraf
DK3143018T3 (da)	2021-05-31	Carboxamidderivater
DK3390422T3 (da)	2023-11-27	Krystalformer af lnt
DK3398598T3 (da)	2022-07-11	Sulfonamidderivat og fremstillingsmetode og anvendelse deraf
DK3386956T3 (da)	2021-10-11	Fumagillolderivater og polymorfer deraf
DK3142655T3 (da)	2021-02-01	Sammensætninger og fremgangsmåder til behandling af hjertefibrose med ifetroban
DK3323485T3 (da)	2020-11-30	Krystalliseringssøjle og krystalliseringsfremgangsmåde
DK3247711T3 (da)	2022-05-09	Hidtil ukendte salte og polymorfer af scy-078
DK3529236T3 (da)	2024-05-13	Krystalformer af eravacyclin
DK3362450T3 (da)	2020-09-14	N1- og N7-substituerede sibirilin-derivater og anvendelse deraf som inhibitorer af cellulær nekroptose